Claims for Patent: 5,580,757

Summary for Patent: 5,580,757

Title:	Cloning and expression of biologically active .alpha.-galactosidase A as a fusion protein
Abstract:	The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described. Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used, but is not limited to, in the treatment in Fabry Disease; for the hydrolysis of .alpha.-galactosyl residues in glycoconjugates; and/or for the conversion of the blood group B antigen on erythrocytes to the blood group O antigen.
Inventor(s):	Desnick; Robert J. (New York, NY), Bishop; David F. (New York, NY), Ioannou; Yiannis A. (New York, NY)
Assignee:	The Mount Sinai School of Medicine of the City University of New York (New York, NY)
Application Number:	08/261,577
Patent Claims:	1. A method of producing human .alpha.-galactosidase A, comprising: a. culturing a mammalian cell transformed with a recombinant vector which includes a nucleotide sequence encoding a cleavage site sandwiched between an .alpha.-galactosidase A coding sequence and a protein A domain E coding sequence arranged in the same translational reading frame, controlled by a second nucleotide sequence that regulates gene expression so that a fusion protein is expressed by the transformed host cell; b. recovering the fusion protein from the culture; c. treating the fusion protein with a substance that cleaves the cleavage site so that the .alpha.-galactosidase A is separated from the protein A domain E protein; and d. recovering the separated .alpha.-galactosidase A. 2. The method according to claim 1 in which the fusion protein is recovered from the culture by reaction with an immunoglobulin binding partner for the protein A domain E protein. 3. The method according to claim 2 in which the immunoglobulin binding partner is immobilized. 4. The method according to claim 1 in which the recombinant vector is pAGA-PA as deposited with the Agricultural Research Culture collection having accession number B-18723. 5. A method of producing human .alpha.-galactosidase A, comprising: a. culturing a mammalian cell transformed with a recombinant vector which includes a nucleotide sequence encoding a cleavage site sandwiched between an .alpha.-galactosidase A coding sequence and a protein antigen coding sequence arranged in the same translational reading frame, controlled by a second nucleotide sequence that regulates gene expression so that a fusion protein is expressed by the transformed host cell; b. recovering the fusion protein from the culture by reaction with an immunoglobulin directed against the protein antigen; c. treating the fusion protein with a substance that cleaves the cleavage site so that the .alpha.-galactosidase A is separated from the protein antigen; and d. recovering the separated .alpha.-galactosidase A. 6. The method according to claim 5 in which the immunoglobulin is immobilized. 7. The method according to claim 1 or 5 in which the substance that cleaves the cleavage site is an enzyme and the cleavage site is a substrate specific for the enzyme. 8. The method according to claim 7 in which the enzyme is collagenase. 9. The method according to claim 1 or 5 in which a .alpha.-galactosidase A coding sequence comprises the sequence depicted in FIG. 1A from nucleotide number 1 to 1299. 10. The method according to claim 1 or 5 in which the .alpha.-galactosidase A coding sequence comprises the sequence depicted in FIG. 1A from nucleotide number 91 to 1299. 11. A recombinant vector comprising a nucleotide sequence encoding a cleavage site sandwiched between an .alpha.-galactosidase A coding sequence and a protein A domain E coding sequence arranged in the same translational reading frame, controlled by a second nucleotide sequence that regulates the expression of a fusion protein in a mammalian host cell. 12. A recombinant vector pAGA-pA as deposited with the Agricultural Research Culture Collection having accession number B 18723. 13. A recombinant vector comprising a nucleotide sequence encoding a cleavage site sandwiched between an .alpha.-galactosidase A coding sequence and a protein antigen coding sequence arranged in the same translational reading frame, controlled by a second nucleotide sequence that regulates the expression of a fusion protein in a mammalian host cell. 14. The recombinant vector of claim 11 or 13 which further includes a nucleotide sequence encoding a selectable marker. 15. The recombinant vector of claim 11 or 13 in which the cleavage site is a collagenase substrate.

Details for Patent 5,580,757

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2013-12-03